From drug­mak­er to drug man­ag­er: Ex-GSK chief An­drew Wit­ty jumps to the helm of gi­ant Op­tum

Over a pe­ri­od of 10 years, An­drew Wit­ty made his rep­u­ta­tion sell­ing drugs around the world as CEO of Lon­don-based Glax­o­SmithK­line.  Now, a year af­ter his re­tire­ment, he’s tak­ing a lead­er­ship role in man­ag­ing drug ben­e­fits in one of the largest, fastest grow­ing out­fits in the US.

Wit­ty has been named the new CEO of Unit­ed­Health’s gi­ant Op­tum di­vi­sion, a phar­ma­cy ben­e­fit man­age­ment group and health­care an­a­lyt­ics com­pa­ny. Now, in­stead of talk­ing about drug pric­ing and ac­cess from a man­u­fac­tur­er’s per­spec­tive, he’ll play a key role in mold­ing re­al-world prac­tices for the world’s biggest drug mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER